Lower toxicity with targeted anticancer agents in phase I trials

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1416, 2012-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Publication biases and phase II trials investigating anticancer targeted therapies

By Penel Nicolas Adenis Antoine

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 287-288

Springer Publishing Company

Access to resources Recommend Favorite

Low skeletal muscle is associated with toxicity in patients included in phase I trials

By Cousin Sophie Hollebecque A. Koscielny S. Mir O. Varga A. Baracos V. Soria J. Antoun S.

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 382-387

Springer Publishing Company

Access to resources Recommend Favorite

Design Issues in Dose-Finding Phase I Trials for Combinations of Two Agents

By Fan Shenghua Kelly

Journal of Biopharmaceutical Statistics, Vol. 19, Iss. 3, 2009-05 ,pp. : 509-523

Taylor & Francis Ltd

Access to resources Recommend Favorite

Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase I trials

By Ederhy Stephane

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 611-615

Springer Publishing Company

Access to resources Recommend Favorite

Marine-derived anticancer agents in clinical trials

By Schwartsmann Gilberto da Rocha Adriana Brondani Mattei Jane Lopes RafaelMartins

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 8, 2003-08 ,pp. : 1367-1383

Informa Healthcare

Access to resources Recommend Favorite